Dr David Britton

Centre for Haemato-Oncology
Postdoctoral Research Assistant
This email address is being protected from spambots. You need JavaScript enabled to view it.

I am experienced in LC-MS/MS proteomics to identify and quantify proteins and their post-translational modifications in pre-clinical samples (cancer cells in culture, xenografts) and clinical biopsies (serum, plasma, blood cells, tissue), with the aim of identifying prognostic and diagnostic markers, as well as drug targets and therefore predictive markers for personalised medicine.

Such proteins may be enzymatic or structural and involved in mechanisms such as cell replication, survival, death, migration, invasion, metabolism, DNA repair, intracellular signalling, epigenetics, transcription and molecular transport.

My project is focussed on determining how these proteins enable acute myeloid leukaemia blasts to acquire or have intrinsic resistance to chemotherapy, with the aim to identify suitable pharmaceutical alternatives to combat resistance.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.